Mark Berger
Chief Tech/Sci/R&D Officer at GENPREX, INC.
Net worth: 14 322 $ as of 2024-03-30
Profile
Mark S.
Berger is currently the Chief Medical Officer at Genprex, Inc. He previously worked as the Senior Director-Oncology Clinical Development at Wyeth Pharmaceuticals LLC, Group Director-Clinical Oncology at GSK Plc, Principal at the University of Pennsylvania, Vice President-Clinical Development at Gemin X Pharmaceuticals US, Inc., Chief Medical Officer at Deciphera Pharmaceuticals LLC, Senior Vice President-Clinical Research at Kadmon Corp.
LLC, and Chief Medical Officer at Actinium Pharmaceuticals, Inc. Berger received his undergraduate degree from Wesleyan University and his doctorate from The University of Virginia School of Medicine.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
GENPREX, INC.
0.32% | 2024-02-17 | 4,806 ( 0.32% ) | 14 322 $ | 2024-03-30 |
Mark Berger active positions
| Companies | Position | Start |
|---|---|---|
| GENPREX, INC. | Chief Tech/Sci/R&D Officer | 2016-12-31 |
Former positions of Mark Berger
| Companies | Position | End |
|---|---|---|
| ACTINIUM PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 2021-09-23 |
Kadmon Corp. LLC
 Kadmon Corp. LLC Pharmaceuticals: MajorHealth Technology Kadmon Corp. LLC manufactures and distributes pharmaceutical products. It currently offers products and services for the treatment and management of hepatitis C, is pioneering medicines in oncology, infectious diseases, and immunology and neurodegenerative diseases by using new understandings in molecular biology to develop therapies that target the metabolomic and signaling pathways associated with disease. The company was founded in 2009 and is headquartered in New York, NY. | Chief Tech/Sci/R&D Officer | 2016-12-31 |
Deciphera Pharmaceuticals LLC
 Deciphera Pharmaceuticals LLC BiotechnologyHealth Technology Deciphera Pharmaceuticals LLC discovers and develops pharmaceutical preparations. It designs kinase inhibitor therapies that target the hallmarks of cancer biology. The firm’s clinical pipeline of kinase inhibitors includes tumor-targeted therapies and immuno-targeted therapies. It offers DCC-2618, Rebastinib, and DCC-3014. The company was founded by Daniel L. Flynn in 2003 and is headquartered in Waltham, MA. | Chief Tech/Sci/R&D Officer | 2013-08-31 |
Gemin X Pharmaceuticals US, Inc.
 Gemin X Pharmaceuticals US, Inc. BiotechnologyHealth Technology Gemin X Pharmaceuticals US Inc. is engaged in the development of cancer therapeutics. It offers mimetic and telomere capping programs, as well as screening, medicinal chemistry, and preclinical development services. The company was founded by Gordon C. Shore in 1998 and is headquartered in Malvern, PA. | Corporate Officer/Principal | 2011-05-31 |
| GSK PLC | Corporate Officer/Principal | 2007-01-31 |
Training of Mark Berger
| Wesleyan University | Undergraduate Degree |
| The University of Virginia School of Medicine | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 3 |
|---|---|
| GENPREX, INC. | Health Technology |
| GSK PLC | Health Technology |
| ACTINIUM PHARMACEUTICALS, INC. | Health Technology |
| Private companies | 4 |
|---|---|
Wyeth Pharmaceuticals LLC
 Wyeth Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Wyeth Pharmaceuticals LLC develops pharmaceutical, biotechnology and vaccine technologies. The company was registered on May 5, 2003 and is headquartered in Collegeville, PA. | Health Technology |
Gemin X Pharmaceuticals US, Inc.
Gemin X Pharmaceuticals US, Inc. BiotechnologyHealth Technology Gemin X Pharmaceuticals US Inc. is engaged in the development of cancer therapeutics. It offers mimetic and telomere capping programs, as well as screening, medicinal chemistry, and preclinical development services. The company was founded by Gordon C. Shore in 1998 and is headquartered in Malvern, PA. | Health Technology |
Deciphera Pharmaceuticals LLC
Deciphera Pharmaceuticals LLC BiotechnologyHealth Technology Deciphera Pharmaceuticals LLC discovers and develops pharmaceutical preparations. It designs kinase inhibitor therapies that target the hallmarks of cancer biology. The firm’s clinical pipeline of kinase inhibitors includes tumor-targeted therapies and immuno-targeted therapies. It offers DCC-2618, Rebastinib, and DCC-3014. The company was founded by Daniel L. Flynn in 2003 and is headquartered in Waltham, MA. | Health Technology |
Kadmon Corp. LLC
Kadmon Corp. LLC Pharmaceuticals: MajorHealth Technology Kadmon Corp. LLC manufactures and distributes pharmaceutical products. It currently offers products and services for the treatment and management of hepatitis C, is pioneering medicines in oncology, infectious diseases, and immunology and neurodegenerative diseases by using new understandings in molecular biology to develop therapies that target the metabolomic and signaling pathways associated with disease. The company was founded in 2009 and is headquartered in New York, NY. | Health Technology |
- Stock Market
- Insiders
- Mark Berger
